Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Ivana Milošević; Jaroslava Jovanović; Olja Stevanovic

doi:10.3855/jidc.13840

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Authors

Ivana Milošević Faculty of Medicine, University of Belgrade, Serbia
Jaroslava Jovanović Faculty of Medicine, University of Belgrade, Serbia
Olja Stevanovic Faculty of Medicine, University of Belgrade, Serbia

DOI:

https://doi.org/10.3855/jidc.13840

Keywords:

COVID-19, agammaglobulinemia, convalescent plasma, IL-6 inhibitor

Abstract

We present atypical course of the novel coronavirus disease (COVID-19) in 34-year man with Bruton agammaglobulinemia. The patient was successfully treated by a combination of available drugs, including convalescent plasma and interleukin-6 (IL-6) inhibitor.

Author Biographies

Ivana Milošević, Faculty of Medicine, University of Belgrade, Serbia

Ivana Milošević is Deputy Director at Clinic for infectious and Tropical Diseases, Clinical Center of Serbia in Belgrade. She is ID specialist and gastroenterohepatologist and head of Hepatology Depatment. She also teaches infectious diseases at Faculty of Medicine, University of Belgrade as associate professor.

Jaroslava Jovanović, Faculty of Medicine, University of Belgrade, Serbia

Jaroslava Jovanović is residant at Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Belgrade, Serbia.

Downloads

Published

2020-11-30

How to Cite

Milošević I, Jovanović J, Stevanovic O (2020) Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. J Infect Dev Ctries 14:1248–1251. doi: 10.3855/jidc.13840

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 14 No. 11: November 2020

Section

Coronavirus Pandemic

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).